{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:09:30Z","timestamp":1761581370633,"version":"build-2065373602"},"reference-count":65,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.hoc.2015.09.008","type":"journal-article","created":{"date-parts":[[2015,11,29]],"date-time":"2015-11-29T14:30:33Z","timestamp":1448807433000},"page":"163-177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors"],"prefix":"10.1016","volume":"30","author":[{"given":"Sujata","family":"Narayanan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela L.","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.hoc.2015.09.008_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ecl.2010.12.005","article-title":"The epidemiology of gastroenteropancreatic neuroendocrine tumors","volume":"40","author":"Lawrence","year":"2011","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"18","key":"10.1016\/j.hoc.2015.09.008_bib2","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2015.09.008_bib3","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/annonc\/mdq022","article-title":"Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE)","volume":"21","author":"Garcia-Carbonero","year":"2010","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2015.09.008_bib4","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1093\/annonc\/mdt377","article-title":"Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n\u00a0= 25 531)","volume":"24","author":"Mocellin","year":"2013","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2015.09.008_bib5","doi-asserted-by":"crossref","first-page":"484","DOI":"10.7326\/0003-4819-129-6-199809150-00011","article-title":"Multiple endocrine neoplasia type 1: clinical and genetic topics","volume":"129","author":"Marx","year":"1998","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.hoc.2015.09.008_bib6","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/hmg\/2.7.851","article-title":"Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC","volume":"2","author":"Donis-Keller","year":"1993","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.hoc.2015.09.008_bib7","series-title":"Nomenclature and classification of neuroendocrine neoplasms of the digestive system. WHO classification of tumours of the digestive system","first-page":"13","author":"Rindi","year":"2010"},{"issue":"11","key":"10.1016\/j.hoc.2015.09.008_bib8","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1056\/NEJM199903183401107","article-title":"Carcinoid tumors","volume":"340","author":"Kulke","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.hoc.2015.09.008_bib9","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1080\/02841860310010547","article-title":"Carcinoid\u2013a comprehensive review","volume":"42","author":"Schnirer","year":"2003","journal-title":"Acta Oncol"},{"issue":"Suppl 7","key":"10.1016\/j.hoc.2015.09.008_bib10","doi-asserted-by":"crossref","first-page":"vii124","DOI":"10.1093\/annonc\/mds295","article-title":"Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Oberg","year":"2012","journal-title":"Ann Oncol"},{"issue":"4068","key":"10.1016\/j.hoc.2015.09.008_bib11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.179.4068.77","article-title":"Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone","volume":"179","author":"Brazeau","year":"1973","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.hoc.2015.09.008_bib12","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1056\/NEJM199601253340408","article-title":"Octreotide","volume":"334","author":"Lamberts","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.hoc.2015.09.008_bib13","first-page":"320","article-title":"Secretion of somatostatin and its physiologic function","volume":"109","author":"Reichlin","year":"1987","journal-title":"J\u00a0Lab Clin Med"},{"issue":"4","key":"10.1016\/j.hoc.2015.09.008_bib14","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/bjc.1998.101","article-title":"Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours","volume":"77","author":"Nilsson","year":"1998","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.hoc.2015.09.008_bib15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2036.2009.04174.x","article-title":"Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours","volume":"31","author":"Modlin","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.hoc.2015.09.008_bib16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.yfrne.2013.07.005","article-title":"Somatostatin receptors: from signaling to clinical practice","volume":"34","author":"Theodoropoulou","year":"2013","journal-title":"Front Neuroendocrinol"},{"issue":"4","key":"10.1016\/j.hoc.2015.09.008_bib17","first-page":"427","article-title":"Molecular biology of somatostatin receptors","volume":"16","author":"Reisine","year":"1995","journal-title":"Endocr Rev"},{"issue":"8","key":"10.1016\/j.hoc.2015.09.008_bib18","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/0024-3205(76)90263-0","article-title":"Differences in the degradation of hypothalamic releasing factors by rat and human serum","volume":"19","author":"Benuck","year":"1976","journal-title":"Life Sci"},{"issue":"24","key":"10.1016\/j.hoc.2015.09.008_bib19","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJM198312153092406","article-title":"Somatostatin","volume":"309","author":"Reichlin","year":"1983","journal-title":"N\u00a0Engl J Med"},{"issue":"4413","key":"10.1016\/j.hoc.2015.09.008_bib20","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1126\/science.382360","article-title":"Somatostatin cell processes as pathways for paracrine secretion","volume":"205","author":"Larsson","year":"1979","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.hoc.2015.09.008_bib21","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1677\/erc.0.0100451","article-title":"Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours","volume":"10","author":"de Herder","year":"2003","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2015.09.008_bib22","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1385\/MO:20:1:59","article-title":"Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors","volume":"20","author":"Fjallskog","year":"2003","journal-title":"Med Oncol"},{"issue":"8079","key":"10.1016\/j.hoc.2015.09.008_bib23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0140-6736(78)91348-X","article-title":"Efficacy of somatostatin in a patient with carcinoid syndrome","volume":"2","author":"Thulin","year":"1978","journal-title":"Lancet"},{"issue":"4366","key":"10.1016\/j.hoc.2015.09.008_bib24","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1126\/science.212832","article-title":"Peptides in the brain: the new endocrinology of the neuron","volume":"202","author":"Guillemin","year":"1978","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.hoc.2015.09.008_bib25","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/annonc\/mdh216","article-title":"Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system","volume":"15","author":"Oberg","year":"2004","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2015.09.008_bib26","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/cncr.23700","article-title":"Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines","volume":"113","author":"Kidd","year":"2008","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.hoc.2015.09.008_bib27","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","article-title":"SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile","volume":"146","author":"Bruns","year":"2002","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.hoc.2015.09.008_bib28","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","article-title":"Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome","volume":"17","author":"Rubin","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2015.09.008_bib29","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.22272","article-title":"Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study","volume":"107","author":"Bajetta","year":"2006","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.hoc.2015.09.008_bib30","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000082875","article-title":"Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide","volume":"80","author":"Ruszniewski","year":"2004","journal-title":"Neuroendocrinology"},{"issue":"2","key":"10.1016\/j.hoc.2015.09.008_bib31","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2011.04693.x","article-title":"Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel)","volume":"34","author":"Khan","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.hoc.2015.09.008_bib32","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0","article-title":"Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance","volume":"88","author":"O'Toole","year":"2000","journal-title":"Cancer"},{"issue":"Suppl 3","key":"10.1016\/j.hoc.2015.09.008_bib33","article-title":"ELECT: a phase 3 study of efficacy and safety of lanreotide autoge\/depot (LAN) treatment for carcinoid syndrome in patient with neuroendocrine tumors (NETs)","volume":"32","author":"Vinik","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2015.09.008_bib34","doi-asserted-by":"crossref","unstructured":"Hobday T, Rubin J, Holen K, et\u00a0al. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a Phase II Consortium (P2C) study. ASCO Annual Meeting June 1\u20135, Chicago, Il, abstract # 4504, 2007.","DOI":"10.1200\/jco.2007.25.18_suppl.4504"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2015.09.008_bib35","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000080741","article-title":"Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors","volume":"80","author":"Schmid","year":"2004","journal-title":"Neuroendocrinology"},{"issue":"Suppl","key":"10.1016\/j.hoc.2015.09.008_bib36","article-title":"A\u00a0multicenter, randomized, blinded, phase III study of pasireotide LAR versus octreotide LAR in patients with metastatic neuroendocrine tumors (NET) with disease-related symptoms inadequately controlled by somatostatin analogs","volume":"31","author":"Wolin","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2015.09.008_bib37","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1097\/MPA.0b013e318279d552","article-title":"Improving the success rate of gluteal intramuscular injections","volume":"42","author":"Boyd","year":"2013","journal-title":"Pancreas"},{"issue":"9","key":"10.1016\/j.hoc.2015.09.008_bib38","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1634\/theoncologist.2014-0120","article-title":"Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study","volume":"19","author":"Strosberg","year":"2014","journal-title":"Oncologist"},{"issue":"13","key":"10.1016\/j.hoc.2015.09.008_bib39","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1002\/cncr.28653","article-title":"Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis","volume":"120","author":"Shen","year":"2014","journal-title":"Cancer"},{"issue":"24 Pt 1","key":"10.1016\/j.hoc.2015.09.008_bib40","first-page":"6977","article-title":"Oncological applications of somatostatin analogues","volume":"48","author":"Schally","year":"1988","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.hoc.2015.09.008_bib41","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/annonc\/mdl105","article-title":"Rationale for the use of somatostatin analogs as antitumor agents","volume":"17","author":"Susini","year":"2006","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2015.09.008_bib42","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1006\/bbrc.2000.2119","article-title":"Effect of somatostatin and octreotide on proliferation and vascular endothelial growth factor secretion from murine endothelial cell line (HECa10) culture","volume":"268","author":"Lawnicka","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"issue":"28","key":"10.1016\/j.hoc.2015.09.008_bib43","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 5s","key":"10.1016\/j.hoc.2015.09.008_bib44","article-title":"Progression-free survival (PFS) with lanreotide autogel\/depot (LAN) in enteropancreatic NETs patients: the CLARINET extension study","volume":"32","author":"Caplin","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2015.09.008_bib45","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/jso.23323","article-title":"Octreotide LAR and bolus octreotide are insufficient for preventing intraoperative complications in carcinoid patients","volume":"107","author":"Massimino","year":"2013","journal-title":"J\u00a0Surg Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2015.09.008_bib46","first-page":"23","article-title":"Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours","volume":"31","author":"Angeletti","year":"1999","journal-title":"Ital J Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.hoc.2015.09.008_bib47","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.2967\/jnumed.111.101675","article-title":"The role of 68Ga-DOTATATE PET\/CT in suspected neuroendocrine tumors. Journal of nuclear medicine : official publication","volume":"53","author":"Haug","year":"2012","journal-title":"J\u00a0Nucl Med"},{"issue":"2","key":"10.1016\/j.hoc.2015.09.008_bib48","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000225952","article-title":"ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: follow-up and documentation","volume":"90","author":"Arnold","year":"2009","journal-title":"Neuroendocrinology"},{"issue":"9","key":"10.1016\/j.hoc.2015.09.008_bib49","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2174\/0929867003374516","article-title":"Receptor targeting for tumor localisation and therapy with radiopeptides","volume":"7","author":"Heppeler","year":"2000","journal-title":"Curr Med Chem"},{"issue":"7","key":"10.1016\/j.hoc.2015.09.008_bib50","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1023\/A:1011160913619","article-title":"The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study","volume":"12","author":"Waldherr","year":"2001","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2015.09.008_bib51","first-page":"610","article-title":"Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. Journal of nuclear medicine : official publication","volume":"43","author":"Waldherr","year":"2002","journal-title":"J\u00a0Nucl Med"},{"issue":"6","key":"10.1016\/j.hoc.2015.09.008_bib52","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/bip.10349","article-title":"90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies","volume":"66","author":"Paganelli","year":"2002","journal-title":"Biopolymers"},{"issue":"2","key":"10.1016\/j.hoc.2015.09.008_bib53","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00259-002-1023-y","article-title":"Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study","volume":"30","author":"Bodei","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"10.1016\/j.hoc.2015.09.008_bib54","first-page":"1556","article-title":"Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors. Journal of nuclear medicine : official publication","volume":"44","author":"Bushnell","year":"2003","journal-title":"J\u00a0Nucl Med"},{"issue":"13","key":"10.1016\/j.hoc.2015.09.008_bib55","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2015.09.008_bib56","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.2967\/jnumed.114.138834","article-title":"Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study","volume":"55","author":"Wild","year":"2014","journal-title":"J\u00a0Nucl Med"},{"issue":"9808","key":"10.1016\/j.hoc.2015.09.008_bib57","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2015.09.008_bib58","unstructured":"Kulke M. A randomized open-label phase II study of everolimus alone or in combination with pasireotide LAR in advanced, progressive pancreatic neuroendocrine tumors: COOPERATE-2 Trial. Presented at 12th Annual ENETS Conference, March 11\u201313, Barcelona, Spain, 2015."},{"issue":"Suppl","key":"10.1016\/j.hoc.2015.09.008_bib59","article-title":"SWOG S0518: phase III prospective randomized comparison of depot octreotide plus interferon alpha-2b versus depot octreotide plus bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients (NCT00569127)","volume":"33","author":"Yao","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.hoc.2015.09.008_bib60","article-title":"Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance)","volume":"33","author":"Kulke","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2015.09.008_bib61","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1038\/sj.bjc.6601346","article-title":"A\u00a0novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839)","volume":"89","author":"Hopfner","year":"2003","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.hoc.2015.09.008_bib62","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2015.09.008_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"issue":"11","key":"10.1016\/j.hoc.2015.09.008_bib64","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1200\/JCO.2005.03.184","article-title":"Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer","volume":"23","author":"Agus","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.hoc.2015.09.008_bib65","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1158\/1078-0432.CCR-04-2642","article-title":"Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy","volume":"11","author":"Friess","year":"2005","journal-title":"Clin Cancer Res"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858815001434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858815001434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:02:23Z","timestamp":1760184143000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858815001434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0889858815001434"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2015.09.008","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2015.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}